Stay updated on Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check15 days agoChange DetectedRevision metadata updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check44 days agoChange DetectedA new Revision: v3.4.2 tag was added and the previous Revision: v3.4.1 tag was removed; no study content, eligibility criteria, or navigation changes are evident.SummaryDifference0.4%

- Check51 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH Clinical Center status, and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check58 days agoChange DetectedGlossary is now shown on the page, and the revision metadata has been updated to v3.4.0. New metadata entries 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' were added, while the previous 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check72 days agoChange DetectedThe page shows Revision: v3.3.4 replacing Revision: v3.3.3; this is a minor version update with no impact on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.